CatenaBio Analysis
What is CatenaBio?
CatenaBio advances therapeutics using innovative protein conjugation technology, specifically the CysTyr™ platform, to develop multi-payload conjugates for improved therapeutic applications.
Product Features & Capabilities
- CysTyr™ platform, Catenase™ enzyme, proprietary C-Y Bond™, multi-payload conjugates, enhanced speed, stability, selectivity, scalability.
Who are the founders of CatenaBio
ML
Marco Lobba
CEO and Co-Founder
MF
Matthew Francis
Co-Founder
Investors
- BrightEdge
- Freeflow Ventures
- LongeVC
- QB3
- Creative Destruction Lab
- California Innovation Fund
- Civilization Ventures
- Pioneer Fund
- Caffeinated Capital
- MBX Capital
Competitors Overview
CatenaBio operates in the biopharmaceutical sector, focusing on next-generation protein conjugation through its proprietary CysTyr™ platform. Its main competitors include:
- Moderna: Known for its mRNA technology, Moderna has a strong position in the vaccine market and is expanding into therap
Market Focus
CatenaBio primarily focuses on the biotechnology industry, specifically in the area of next-generation protein conjugation and the development of innovative therapeutics.
See something that needs updating? Suggest edits to this profile.